medicina61巻9号

2024年08月発行

特集 リウマチ膠原病疾患Up To Date！—押さえておきたい最新の診断と治療 膠原病の診断と治療

全身性強皮症の診断と治療

著者： 安岡秀剛¹

所属機関： ¹藤田医科大学リウマチ・膠原病内科学講座

ページ範囲：P.1481 - P.1484

Point
◎全身性強皮症は皮膚および全身諸臓器の過剰な線維化および血管障害が重要な問題となる．
◎病態としては線維化・リモデリングが関わっているが，メカニズムは十分に明らかでなく，治療法の確立には至っていない．
◎近年この領域における治療薬の開発が進み，生物学的製剤や分子標的治療および抗線維化薬が応用されるようになってきた．

参考文献

1）Denton CP, et al：Targeted therapy comes of age in scleroderma. Trends Immunol 26：596-602, 2005 PMID 16168710

2）LeRoy EC, et al：Scleroderma（systemic sclerosis）；Classification, subsets and pathogenesis. J Rheumatol 15：202-205, 1988 PMID 3361530

3）Matucci-Cerinic M, et al：The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group（EUSTAR）community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68：1377-1380, 2009 PMID 19674983

4）van den Hoogen F, et al：2013 classification criteria for systemic sclerosis；An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65：2737-2747, 2013 PMID 24122180

5）Trojanowska M：Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6：453-60, 2020 PMID 20585340

6）Launay D, et al：Pulmonary hypertension in systemic sclerosis. Eur Respir Rev 26：170056, 2017 PMID 28954767

7）Sasaki N, et al：A histopathological study of pulmonary hypertension in connective tissue disease. Allergol Int 60：411-417, 2011 PMID 21918364

8）Chatterjee S：Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum 41：19-37, 2011 PMID 21047671

9）Tashkin DP, et al：Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med 354：2655-2666, 2006 PMID 16790698

10）Tashkin DP, et al：Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related in terstitial lung disease（SLS Ⅱ）；A randomized controlled, double-blind, parallel group trial. Lancet Respir Med 4：708-719, 2016 PMID 27469583

11）Khanna D, et al：Tocilizumab in systemic sclerosis；A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8：963-974, 2020 PMID 32866440

12）Hasegawa M：B lymphocytes；Shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 37：3-10, 2010 PMID 20175836

13）Ebata S, et al：Safety and efficacy of rituximab in systemic sclerosis（DESIRES）；A double-blind, investigator-initiated, randomized, placebo-controlled trial. Lancet Rheumatol 3：E489-497, 2021 PMID 38279402

14）Briggs DC, et al：Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 338：661-662, 1991 PMID 1679476

15）Jiang Y, et al：Factors associated with pulmonary arterial hypertension（PAH）in systemic sclerosis（SSc）. Autoimmunity Rev 19：102602, 2020 PMID 32659476

16）Hamaguchi Y, et al：High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Mod Rheumatol 25：798-801, 2015 PMID 24252018

17）Moinzadeh P, et al：Association of anti-RNA polymerase Ⅲ autoantibodies and cancer in scleroderma. Arthritis Res Ther 16：R53, 2014 PMID 24524733